Three ways to work with the FDA for better patient-focused trials
Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.
This article covers three useful practices for getting the most out of your collaboration.
Related Insights
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Including patients in DCT design
Sep 13, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Related Insights
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Including patients in DCT design
Sep 13, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023